Evidence map›Paper›PMID 37860820›Full record

ReviewFrontiers in cell and developmental biology2023

Positioning SUMO as an immunological facilitator of oncolytic viruses for high-grade glioma.

Paramesh V Karandikar, Lyle Suh, Jakob V E Gerstl, Sarah E Blitz, Qing Rui Qu, Sae-Yeon Won, Florian A Gessler, Omar Arnaout, Timothy R Smith, Pier Paolo Peruzzi and 3 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cell and developmental biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Case Report: Low-grade glioma withFrontiers in surgery · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Paramesh V KarandikarT. H. Chan School of Medicine, University of Massachusetts, Worcester, MA, United States.
Lyle SuhT. H. Chan School of Medicine, University of Massachusetts, Worcester, MA, United States.
Jakob V E GerstlDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Sarah E BlitzDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Qing Rui QuDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Sae-Yeon WonDepartment of Neurosurgery, University of Rostock, Rostock, Germany.
Florian A GesslerDepartment of Neurosurgery, University of Rostock, Rostock, Germany.
Omar ArnaoutDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Timothy R SmithDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Pier Paolo PeruzziDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Wei YangDepartment of Anesthesiology, Multidisciplinary Brain Protection Program, Duke University Medical Center, Durham, NC, United States.
Gregory K FriedmanDepartment of Neuro-Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, United States.
Joshua D BernstockDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Brigham and Women's Hospital · USUniversity of Rostock · DEDuke Medical Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of Massachusetts Chan Medical School · US

Funding

Harnessing Artificial MicroRNA Clusters Against Glioblastoma Epigenetic Plasticity and Resistance to TherapyR01NS116144 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI PERUZZI, PIER PAOLO · 2020 to 2025
$2.1M
FDA HHS R01 FD006368NINDS NIH HHS R01 NS116144
6 · The paper itself

Abstract

Oncolytic viral (OV) therapies are promising novel treatment modalities for cancers refractory to conventional treatment, such as glioblastoma, within the central nervous system (CNS). Although OVs have received regulatory approval for use in the CNS, efficacy is hampered by obstacles related to delivery, under-/over-active immune responses, and the "immune-cold" nature of most CNS malignancies. SUMO, the Small Ubiquitin-like Modifier, is a family of proteins that serve as a high-level regulator of a large variety of key physiologic processes including the host immune response. The SUMO pathway has also been implicated in the pathogenesis of both wild-type viruses and CNS malignancies. As such, the intersection of OV biology with the SUMO pathway makes SUMOtherapeutics particularly interesting as adjuvant therapies for the enhancement of OV efficacy alone and in concert with other immunotherapeutic agents. Accordingly, the authors herein provide: 1) an overview of the SUMO pathway and its role in CNS malignancies; 2) describe the current state of CNS-targeted OVs; and 3) describe the interplay between the SUMO pathway and the viral lifecycle and host immune response.

Indexed as

cancer immunotherapieshigh-grade gliomaoncolytic virusesSUMOSUMOtherapeutics

Identifiers

PMID37860820
PMCPMC10582965
OpenAlexW4387393719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.